Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NLM-001 and Zalifrelimab with Chemotherapy in Advanced Pancreatic Cancer
NCT04827953Phase 2Active, not recruiting
- Sponsor
- Nelum
- Start
- Sep 2021
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TAK-441 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Nelum. Started Sep 2021; status: active, not recruiting.
02
Drugs
TAK-441
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04827953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04827953.